The influence of biological and technical factors on quantitative analysis of amyloid PET: Points to consider and recommendations for controlling variability in longitudinal data-Reference-Cited by-同舟云学术

The influence of biological and technical factors on quantitative analysis of amyloid PET: Points to consider and recommendations for controlling variability in longitudinal data

Published:2014-11-24 Issue:9 Volume:11 Page:1050-1068
ISSN:1552-5260
Container-title:Alzheimer's & Dementia
language:en
Short-container-title:Alzheimer's & Dementia

Author:

Schmidt Mark E.¹,Chiao Ping²,Klein Gregory³,Matthews Dawn⁴,Thurfjell Lennart⁵,Cole Patricia E.⁶,Margolin Richard⁷,Landau Susan⁸,Foster Norman L.⁹,Mason N. Scott¹⁰,Santi Susan¹¹,Suhy Joyce³,Koeppe Robert A.¹²,Jagust William⁸,

Affiliation:

1. Janssen Pharmaceutica Beerse Belgium

2. Biogen IDEC Cambridge MA USA

3. Synarc Newark CA USA

4. ADM Diagnostics LLC Chicago IL USA

5. GE Healthcare Uppsala Sweden

6. Takeda Pharmaceuticals Deerfield IL USA

7. CereSpir, Inc. New York NY USA

8. Helen Wills Neuroscience Institute University of California Berkeley, Berkeley CA USA

9. Division of Cognitive Neurology University of Utah Salt Lake City UT USA

10. Department of Radiology University of Pittsburgh Pittsburgh PA USA

11. Piramal Imaging Boston MA USA

12. Division of Nuclear Medicine University of Michigan Ann Arbor MI USA

Funder

National Institutes of Health

National Institute on Aging

National Institute of Biomedical Imaging and Bioengineering

Northern California Institute for Research and Education

Alzheimer's Disease Neuroimaging Initiative

Alzheimer's Association

Alzheimer’s Drug Discovery Foundation

BioClinica, Inc.

Biogen Idec Inc.

Bristol-Myers Squibb Company

Eisai Inc.

Elan Pharmaceuticals, Inc.

Eli Lilly and Company

F. Hoffmann-La Roche Ltd

Genentech, Inc.

GE Healthcare

Innogenetics, N.V.

IXICO Ltd.

Janssen Alzheimer Immunotherapy Research & Development, LLC.

Johnson & Johnson Pharmaceutical Research & Development LLC.

Medpace, Inc.

Merck & Co., Inc.

Meso Scale Diagnostics, LLC.

NeuroRx Research

Novartis Pharmaceuticals Corporation

Pfizer Inc.

Piramal Imaging

Servier

Synarc Inc.

Takeda Pharmaceutical Company

Canadian Institutes of Health Research

Publisher

Wiley

Subject

Psychiatry and Mental health,Cellular and Molecular Neuroscience,Geriatrics and Gerontology,Clinical Neurology,Developmental Neuroscience,Health Policy,Epidemiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1016/j.jalz.2014.09.004

Reference118 articles.

1. Use of Florbetapir-PET for Imaging β-Amyloid Pathology

2. Available from:http://www.amyvid.com/Pages/reader‐training‐program.aspx.

3. (QIBA) Q.I.B.A. QIBA Profile. FDG‐PET/CT as an imaging biomarker.3. Measuring response to cancer therapy. 2013.

4. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0

5. The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core

Cited by 99 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Visual assessments of 11C-Pittsburgh compound-B PET vs. 18F-flutemetamol PET across the age spectrum;Nuclear Medicine Communications;2024-09-13

2. Change in Depressive Symptoms and Longitudinal Regional Amyloid Accumulation in Unimpaired Older Adults;JAMA Network Open;2024-08-29

3. Harmonizing tau positron emission tomography in Alzheimer's disease: The CenTauR scale and the joint propagation model;Alzheimer's & Dementia;2024-07-23

4. Stress testing the Centiloid: Precision and variability of PET quantification of amyloid pathology;Alzheimer's & Dementia;2024-07-04

5. Deep learning-based amyloid PET harmonization to predict cognitive decline in non-demented elderly;Radiology Advances;2024-05-28